Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

OncLive’s November Roundup of Key FDA Approvals in Oncology

December 3rd 2024

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

Revisit Every OncLive On Air Episode From November 2024

December 2nd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Eflornithine Plus Lomustine Demonstrates Clinically Meaningful Survival Benefits in Grade III IDH-Mutant Astrocytoma

December 2nd 2024

Rimas V. Lukas, MD, discusses the potential role for eflornithine plus lomustine in recurrent grade 3 IDH-mutant astrocytoma.

Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors

November 26th 2024

Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.

Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.

The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors

November 26th 2024

Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.

Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma

November 25th 2024

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

FDA Approves Companion Diagnostic for Zanidatamab in HER2+ Biliary Tract Cancer

November 25th 2024

The FDA approved the PATHWAY HER2 (4B5) test to identify patients with HER2-positive biliary tract cancer who are eligible for treatment with zanidatamab.

Adding an HPK1 Inhibitor to Immune Checkpoint Inhibition May Be Effective in Solid Tumors

November 22nd 2024

Anita Scheuber, MD, PhD, details how HPK1 inhibition may enhance the antitumor activity of ICIs in solid tumors, diving into the agent NDI-101150 in particular.

Dr Pobel on the Prognostic Value of Phenotypic and Genomic Characterization in De Novo mCSPC

November 20th 2024

Cedric Pobel, MD, discusses the potential prognostic value of phenotypic and genomic characterization of de novo mCSPC from the phase 3 PEACE-1 trial.

FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors

November 19th 2024

The FDA granted fast track designation to ALE.P02 for CLDN1-positive squamous solid tumors.

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

November 15th 2024

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors

November 15th 2024

The CHMP has recommended repotrectinib for ROS1-positive non–small cell lung cancer and NTRK-positive solid tumors.

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

November 14th 2024

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

November 12th 2024

Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia.

Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.

The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.